Pembrolizumab outcomes study in cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tracks how well pembrolizumab works in people with cervical cancer that has come back, spread, or not gone away. It includes two groups: one for those currently on or starting the drug, and one for those who stop early due to a good response or side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that is persistent, came back, or spread to other parts of your body.
- You are currently taking or about to start a treatment plan that includes pembrolizumab.
- For the early stop group: you have been on pembrolizumab for at least 8 cycles and had a complete or partial response for at least 9 weeks, or you stop due to serious side effects.
- You do not have another cancer that needs treatment (except for some skin cancers or early-stage cancers that were cured).
- You are willing and able to come to clinic visits, get CT scans, and fill out questionnaires.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
This trial tests a new drug combination for people with cervical or endometrial cancer that has come back or spread. The study aims to see if adding BL-B01D1 to Keytruda (with or without Avastin) can help shrink tumors or slow the cancer's growth.
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
This trial tests a new experimental drug, PRGN-2009, combined with the immunotherapy pembrolizumab (Keytruda) for people with HPV-related cervical cancer that has come back or spread. It is for those who have already tried pembrolizumab and are looking for another option.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.